Enanta Pharmaceuticals Inc (ENTA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $320.09M
Last updated: Nov 17, 2026 at 11:05 AM ET
Enanta Pharmaceuticals Inc (ENTA) Earnings: Report Dates and Results
Enanta Pharmaceuticals (ENTA) is expected to report earnings on Feb 8, 2027. In the quarter ended Jun 30, 2026, Enanta Pharmaceuticals reported EPS of -$0.67, below the -$0.37 estimate. It beat the EPS estimate in 6 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
ENTA has an expected report date of Feb 8, 2027.
ENTA Earnings Call
The latest ENTA earnings call transcript on file is labeled 2024Q2.
Read the 2024Q2 transcriptEarnings History
Of the 40 quarters below that had an estimate, ENTA beat 26 and missed 14. Revenue for the quarter ended Jun 30, 2026 was $14.36M, down 21.6% from $18.31M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | -$0.67 | -$0.37 | -$0.77 - -$0.22 | -81.08% | Miss | N/A | 5 | 2 up, 0 down | Aug 10, 2026 | $14.36M |
| Mar 31, 2026 | -$0.45 | -$0.57 | N/A | +21.05% | Beat | N/A | 5 | 2 up, 0 down | May 11, 2026 | $17.16M |
| Dec 31, 2025 | -$0.42 | -$0.88 | -$1.23 - -$0.53 | +52.27% | Beat | N/A | 5 | 1 up, 1 down | Feb 9, 2026 | $18.61M |
| Sep 30, 2025 | -$0.87 | -$1.01 | -$1.19 - -$0.88 | +13.86% | Beat | N/A | 5 | N/A | Nov 17, 2025 | $15.13M |
| Jun 30, 2025 | -$0.85 | -$0.88 | -$1.68 - $0.55 | +3.41% | Beat | N/A | 4 | 0 up, 2 down | Aug 11, 2025 | $18.31M |
| Mar 31, 2025 | -$1.06 | -$1.14 | -$1.42 - -$0.98 | +7.02% | Beat | N/A | 5 | 2 up, 0 down | May 12, 2025 | $14.93M |
| Dec 31, 2024 | -$1.05 | -$1.35 | -$1.50 - -$1.16 | +22.22% | Beat | N/A | 4 | 0 up, 3 down | Feb 10, 2025 | $16.96M |
| Sep 30, 2024 | -$1.36 | -$0.92 | -$1.50 - -$0.07 | -47.83% | Miss | N/A | 5 | 3 up, 1 down | Nov 25, 2024 | $14.61M |
| Jun 30, 2024 | -$1.07 | -$1.41 | -$1.73 - -$1.18 | +24.11% | Beat | N/A | 7 | 0 up, 0 down | Aug 5, 2024 | $17.97M |
| Mar 31, 2024 | -$1.47 | -$1.40 | -$1.63 - -$1.11 | -5.00% | Miss | N/A | 7 | 0 up, 0 down | May 6, 2024 | $17.05M |
| Dec 31, 2023 | -$1.58 | -$1.23 | -$1.70 - -$0.90 | -28.46% | Miss | N/A | 5 | 0 up, 0 down | Feb 7, 2024 | $18.00M |
| Sep 30, 2023 | -$1.33 | -$2.21 | -$2.35 - -$1.68 | +39.82% | Beat | N/A | 6 | 0 up, 0 down | Nov 20, 2023 | $18.93M |
| Jun 30, 2023 | -$1.86 | -$2.19 | -$2.97 - -$1.86 | +15.07% | Beat | N/A | 6 | 0 up, 0 down | Aug 7, 2023 | $18.89M |
| Mar 31, 2023 | -$1.79 | -$1.93 | -$2.30 - -$1.39 | +7.25% | Beat | N/A | 8 | 0 up, 0 down | May 8, 2023 | $17.80M |
| Dec 31, 2022 | -$1.39 | -$1.60 | -$1.81 - -$1.37 | +13.13% | Beat | N/A | 6 | 2 up, 0 down | Feb 7, 2023 | $23.59M |
| Sep 30, 2022 | -$1.27 | -$1.35 | -$1.61 - -$1.10 | +5.93% | Beat | N/A | 7 | 0 up, 0 down | Nov 21, 2022 | $20.32M |
| Jun 30, 2022 | -$1.53 | -$1.39 | -$1.71 - -$0.83 | -10.07% | Miss | N/A | 8 | 1 up, 1 down | Aug 8, 2022 | $19.48M |
| Mar 31, 2022 | -$1.63 | -$1.41 | -$1.82 - -$1.19 | -15.60% | Miss | N/A | 9 | 0 up, 0 down | May 9, 2022 | $18.72M |
| Dec 31, 2021 | -$1.48 | -$1.11 | -$1.43 - -$0.77 | -33.33% | Miss | N/A | 8 | N/A | Feb 8, 2022 | $27.65M |
| Sep 30, 2021 | -$1.22 | -$1.19 | -$1.59 - -$0.60 | -2.52% | Miss | N/A | 9 | N/A | Nov 22, 2021 | $23.57M |
| Jun 30, 2021 | -$1.19 | -$1.29 | -$1.47 - -$1.02 | +7.75% | Beat | N/A | 8 | N/A | Aug 5, 2021 | $21.62M |
| Mar 31, 2021 | -$1.09 | -$0.97 | -$1.13 - -$0.51 | -12.37% | Miss | N/A | 8 | N/A | May 6, 2021 | $20.13M |
| Dec 31, 2020 | -$0.41 | -$0.77 | -$1.02 - -$0.58 | +46.75% | Beat | -163.1% | 7 | N/A | Feb 8, 2021 | $31.74M |
| Sep 30, 2020 | -$1.46 | -$0.97 | -$1.29 - -$0.71 | -50.52% | Miss | -431.8% | 7 | N/A | Nov 23, 2020 | $23.63M |
| Jun 30, 2020 | -$0.71 | -$0.96 | -$1.25 - -$0.26 | +26.04% | Beat | -315.2% | 6 | N/A | Aug 4, 2020 | $18.65M |
| Mar 31, 2020 | -$0.30 | -$0.72 | -$1.80 - -$0.45 | +58.33% | Beat | -250.0% | 7 | N/A | May 6, 2020 | $27.62M |
| Dec 31, 2019 | $0.65 | $0.60 | $0.38 - $0.76 | +8.33% | Beat | -48.0% | 6 | N/A | Feb 6, 2020 | $52.57M |
| Sep 30, 2019 | $0.44 | $0.56 | $0.34 - $1.10 | -21.43% | Miss | -66.2% | 7 | N/A | Nov 21, 2019 | $51.31M |
| Jun 30, 2019 | $0.33 | $0.17 | $0.01 - $0.51 | +94.12% | Beat | -66.0% | 7 | N/A | Aug 6, 2019 | $44.37M |
| Mar 31, 2019 | $0.20 | -$0.05 | -$0.30 - $0.20 | +500.00% | Beat | -67.2% | 7 | N/A | May 7, 2019 | $39.63M |
| Dec 31, 2018 | $1.25 | $1.29 | $1.10 - $1.72 | -3.10% | Miss | +212.5% | 7 | N/A | Feb 6, 2019 | $69.89M |
| Sep 30, 2018 | $1.30 | $1.19 | $1.05 - $1.33 | +9.24% | Beat | -30.1% | 6 | N/A | Nov 26, 2018 | $67.20M |
| Jun 30, 2018 | $0.97 | $0.90 | $0.68 - $1.18 | +7.78% | Beat | N/A | 6 | N/A | Aug 7, 2018 | $57.26M |
| Mar 31, 2018 | $0.61 | $0.25 | $0.12 - $0.87 | +144.00% | Beat | N/A | 4 | N/A | May 8, 2018 | $44.05M |
| Dec 31, 2017 | $0.40 | $0.27 | -$0.04 - $0.36 | +48.15% | Beat | N/A | 4 | N/A | Feb 7, 2018 | $38.11M |
| Sep 30, 2017 | $1.86 | $2.13 | $1.81 - $2.83 | -12.68% | Miss | N/A | 4 | N/A | Nov 20, 2017 | $75.93M |
| Jun 30, 2017 | -$0.44 | -$0.48 | -$0.59 - -$0.39 | +8.33% | Beat | N/A | 3 | N/A | Aug 7, 2017 | $7.51M |
| Mar 31, 2017 | -$0.28 | -$0.38 | N/A | +26.32% | Beat | N/A | N/A | N/A | May 8, 2017 | $8.96M |
| Dec 31, 2016 | -$0.26 | -$0.18 | N/A | -44.44% | Miss | -119.1% | N/A | N/A | Feb 8, 2017 | $10.42M |
| Sep 30, 2016 | -$0.09 | -$0.18 | N/A | +50.00% | Beat | -131.0% | N/A | N/A | Nov 21, 2016 | $12.84M |
Annual EPS
EPS for the fiscal year ended Sep 30, 2026 was -$1.54, after -$3.83 the year before. It was $0.88 for the year ended Sep 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Sep 30, 2026 | -$1.54 | N/A |
| Sep 30, 2025 | -$3.83 | N/A |
| Sep 30, 2024 | -$5.48 | N/A |
| Sep 30, 2023 | -$6.37 | N/A |
| Sep 30, 2022 | -$5.91 | N/A |
| Sep 30, 2021 | -$3.91 | N/A |
| Sep 30, 2020 | -$1.82 | -182.0% |
| Sep 30, 2019 | $2.22 | -32.3% |
| Sep 30, 2018 | $3.28 | +272.7% |
| Sep 30, 2017 | $0.88 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q2 for the period ended Jun 30, 2024, runs about 5,200 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q2 | Jun 30, 2024 | 5,218 | 12 |
2024Q2 Earnings Call
Opening remarks
Jennifer Viera Investor Relations Thank you, operator, and thanks to everyone for joining us this afternoon. The news release with our fiscal second quarter financial results was issued this afternoon and is available on our website. Making remarks on today's call are Dr. Jay Luly, President and Chief Executive Officer; and Paul Mellett, our Chief Financial Officer. Dr. Scott Rottinghaus, our Chief Medical Officer; and Dr. Tara Kieffer, our Chief Product Strategy Officer, will be available during the Q&A portion of the call. Before we begin with our formal remarks, we want to remind you that we will be making forward-looking statements. These statements may include our plans and expectations with respect to our research and development pipeline and financial projections. All of these statements involve certain assumptions and risks beyond our control that could cause our actual developments and results to differ materially from the statements. A description of these risks is in our most recent Form 10-K and other periodic reports filed with the SEC. Enanta does not undertake any obligation to update any forward-looking statements made during this call. I'd now like to turn the call over to Dr. Jay Luly, President and CEO. Jay?
Jay Luly President and CEO Thank you, Jennifer, and good afternoon, everyone. Throughout 2024, Enanta has remained squarely focused on advancing our virology and immunology pipeline to bring important oral therapeutics to market. Our commitment to developing treatments for areas of high unmet need is driven by our mission to transform patients' lives with curative therapies. And we are determined to achieve our milestones to drive near- and long-term shareholder value to fulfill this mission. Our focus is critical as we approach meaningful inflection points with the potential to develop the first antiviral treatment for RSV. With that, today, I'll begin with an overview of our programs, beginning with our respiratory syncytial virus or RSV programs and then discuss our immunology program for chronic spontaneous urticaria or CSU. As a reminder, RSV is a severe respiratory infection associated with significant morbidity and mortality that can cause serious disease in infants, children, and other high-risk populations, including the elderly and individuals with congestive heart failure, chronic obstructive pulmonary disease, asthma, or other high-risk conditions. Despite the availability of prophylactic options such as vaccines and monoclonal antibodies, there's a clear need for a safe and effective oral RSV antiviral treatment. Adoption of vaccines has been suboptimal, and breakthrough infections still occur. Additionally, pediatric monoclonal antibodies only provide passive immunity for a few months and not long-term protection against the infection. With this clear need, we have developed a broad clinical program that has the potential to enable multiple opportunities to treat RSV.
Frequently Asked Questions About ENTA
When is Enanta Pharmaceuticals's next earnings date?
Enanta Pharmaceuticals's next earnings report is expected for Feb 8, 2027.
Did ENTA beat earnings estimates last quarter?
No. Enanta Pharmaceuticals reported EPS of -$0.67 for the quarter ended Jun 30, 2026, below the -$0.37 estimate by 81.08%.
What EPS do analysts expect from ENTA next quarter?
The consensus EPS estimate for Enanta Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.41 from 2 analysts, with estimates from -$0.48 to -$0.33.
How often does ENTA beat earnings estimates?
Enanta Pharmaceuticals beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of -1.13%.
ENTA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors